tiprankstipranks
Advertisement

XHS - ETF AI Analysis

Compare

Top Page

XHS

SPDR S&P Health Care Services ETF (XHS)

Rating:67Neutral
Price Target:
XHS, the SPDR S&P Health Care Services ETF, earns a solid overall rating driven by strong contributors like Progyny, Elevance Health, HealthEquity, and Pediatrix, which show robust financial performance, positive earnings calls, and strategic growth initiatives. However, holdings such as DaVita and Guardant Health, which face profitability, financial stability, and momentum challenges, modestly weigh on the fund’s appeal. The main risk factor is its focus on health care services, meaning the ETF is sensitive to sector-specific issues like reimbursement changes, regulation, and healthcare cost pressures.
Positive Factors
Broad Health Care Services Focus
The fund is heavily invested in health care services companies, giving investors targeted exposure to a key part of the health care industry.
Balanced Top Holdings
The largest positions each make up only a small slice of the portfolio, which helps reduce the impact of any single stock on overall returns.
Several Strong-Performing Holdings
A number of the top holdings have shown strong gains so far this year, which has supported the ETF’s overall performance.
Negative Factors
Single-Sector Concentration
Almost all assets are in the health care sector, so the fund could be hit hard if health care services stocks fall out of favor.
Limited Geographic Diversification
With nearly all exposure in U.S. companies, the ETF offers little protection if the U.S. market or health care policy environment weakens.
Mixed Performance Among Top Holdings
Some of the largest positions have shown weak or negative results this year, which can drag on the fund’s overall returns despite its recent short-term strength.

XHS vs. SPDR S&P 500 ETF (SPY)

XHS Summary

XHS is the SPDR S&P Health Care Services ETF, which follows the S&P Health Care Services Select Industry Index. It focuses on U.S. companies that provide medical care and related services, such as hospitals, health insurers, and outpatient clinics. Well-known holdings include UnitedHealth and Humana. Someone might invest in XHS to gain targeted exposure to the health care services theme, which can benefit from an aging population and steady demand for medical care. A key risk is that it is concentrated in one sector, so its price can rise or fall sharply with changes in health care policy and industry conditions.
How much will it cost me?The SPDR S&P Health Care Services ETF (XHS) has an expense ratio of 0.35%, meaning you’ll pay $3.50 per year for every $1,000 invested. This is slightly higher than average for ETFs because it is a sector-focused fund, which typically requires more active management compared to broad-market index funds.
What would affect this ETF?The SPDR S&P Health Care Services ETF (XHS) could benefit from increasing demand for health care services driven by an aging population and advancements in medical technology, which support innovation and growth in its top holdings like NeoGenomics and Guardant Health. However, potential risks include regulatory changes or shifts in government health care policies that could impact profitability, as well as broader economic conditions that may affect consumer spending on health care services. With its strong focus on U.S.-based health care providers, the ETF is well-positioned to capitalize on the sector's resilience but remains sensitive to policy and economic fluctuations.

XHS Top 10 Holdings

XHS is very much a U.S. health‑care services story, with performance driven by a mix of rising managed-care and specialty providers. Acadia Healthcare and Astrana Health have been climbing, giving the fund a helpful tailwind, while BrightSpring and Pediatrix add steady support as they grow into their expansion plans. On the flip side, big insurers like Humana and Elevance Health have been more mixed, occasionally losing steam and muting gains. With nearly everything tied to health‑care services, the ETF is concentrated in one theme but spread across many individual names.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
Humana2.35%$2.19M$25.84B-15.04%
69
Neutral
UnitedHealth2.32%$2.17M$322.15B-15.55%
72
Outperform
Astrana Health2.24%$2.10M$1.52B10.64%
56
Neutral
Molina Healthcare2.23%$2.09M$9.17B-44.03%
71
Outperform
Elevance Health2.22%$2.07M$74.87B-13.94%
76
Outperform
Hims & Hers Health2.20%$2.05M$6.97B3.20%
68
Neutral
Alignment Healthcare2.19%$2.04M$4.32B18.43%
60
Neutral
Centene2.17%$2.03M$20.57B-26.85%
58
Neutral
BrightSpring Health Services, Inc.2.17%$2.03M$9.30B180.59%
67
Neutral
Pediatrix Medical Group2.17%$2.03M$1.91B89.24%
76
Outperform

XHS Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
105.33
Positive
100DMA
106.83
Positive
200DMA
103.17
Positive
Market Momentum
MACD
1.73
Negative
RSI
69.29
Neutral
STOCH
93.44
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For XHS, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 106.94, equal to the 50-day MA of 105.33, and equal to the 200-day MA of 103.17, indicating a bullish trend. The MACD of 1.73 indicates Negative momentum. The RSI at 69.29 is Neutral, neither overbought nor oversold. The STOCH value of 93.44 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XHS.

XHS Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$98.07M0.35%
67
Neutral
$99.54M0.54%
53
Neutral
$67.02M0.19%
65
Neutral
$59.56M0.34%
60
Neutral
$39.39M0.65%
48
Neutral
$30.57M0.60%
72
Outperform
Performance Comparison
Ticker
Company Name
Price
Change
% Change
XHS
SPDR S&P Health Care Services ETF
110.53
14.00
14.50%
LFSC
F/M Emerald Life Sciences Innovation ETF
IBBQ
Invesco Nasdaq Biotechnology ETF
BBP
Virtus LifeSci Biotech Products ETF
BBC
Virtus LifeSci Biotech Clinical Trials ETF
FTXH
First Trust Nasdaq Pharmaceuticals ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement